Literature DB >> 31463125

Validation of the 8th edition of the TNM staging system in 3,950 patients with surgically resected non-small cell lung cancer.

Jae Kwang Yun1, Geun Dong Lee1, Hyeong Ryul Kim1, Yong-Hee Kim1, Dong Kwan Kim1, Seung-Il Park1, Sehoon Choi1.   

Abstract

BACKGROUND: The International Association for the Study of Lung Cancer introduced the 8th edition of the tumor, node, and metastasis (TNM) staging system for lung cancer. In this study, we validated the 8th edition of the TNM staging system and compared its discrimination power with that of the previous 7th edition.
METHODS: A retrospective analysis was carried out on patients who underwent complete resection with systematic lymph node dissection for non-small cell lung cancer (NSCLC) between 2006 and 2015 at a tertiary referral center in Seoul, South Korea. Cox regression model was used to identify significant differences between adjacent TNM stage groupings. The Concordance index (C-index), Akaike Information Criterion (AIC), and R2 measure were utilized to evaluate the discrimination ability of the staging systems.
RESULTS: A total of 3,950 patients (2,440 male, median age: 63 years) were analyzed. Median follow-up was 59 months (interquartile ranges, 38-88 months). According to the 8th edition, survival curves of overall survival (OS) and recurrence-free survival (RFS) within adjacent stage groupings showed significant differences except for IIA vs. IIB. Compared with the 7th edition, the 8th edition showed higher C-index (0.753 vs. 0.751), lower AIC (17,517 vs. 17,543), and higher R2 (0.178 vs. 0.171) values, indicating better discrimination ability.
CONCLUSIONS: Stratification based on the 8th edition of the TNM staging system showed favorable prognostic validity compared with the 7th edition. The 8th edition also had superior discrimination ability in terms of OS and RFS.

Entities:  

Keywords:  Lung cancer; external validation; lung cancer staging; tumor, node, and metastasis classification (TNM classification)

Year:  2019        PMID: 31463125      PMCID: PMC6687999          DOI: 10.21037/jtd.2019.07.43

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN: 2072-1439            Impact factor:   2.895


  25 in total

1.  The problem of overfitting.

Authors:  Douglas M Hawkins
Journal:  J Chem Inf Comput Sci       Date:  2004 Jan-Feb

2.  Evaluation of the new TNM staging system proposed by the International Association for the Study of Lung Cancer at a single institution.

Authors:  Kotaro Kameyama; Mamoru Takahashi; Keiji Ohata; Hitoshi Igai; Akihiko Yamashina; Tomoaki Matsuoka; Tatsuo Nakagawa; Norihito Okumura
Journal:  J Thorac Cardiovasc Surg       Date:  2009-03-09       Impact factor: 5.209

3.  Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups.

Authors:  Gary M Strauss; James E Herndon; Michael A Maddaus; David W Johnstone; Elizabeth A Johnson; David H Harpole; Heidi H Gillenwater; Dorothy M Watson; David J Sugarbaker; Richard L Schilsky; Everett E Vokes; Mark R Green
Journal:  J Clin Oncol       Date:  2008-09-22       Impact factor: 44.544

4.  An empirical approach to model selection through validation for censored survival data.

Authors:  Ickwon Choi; Brian J Wells; Changhong Yu; Michael W Kattan
Journal:  J Biomed Inform       Date:  2011-02-16       Impact factor: 6.317

5.  On the prognostic value of survival models with application to gene expression signatures.

Authors:  T Hielscher; M Zucknick; W Werft; A Benner
Journal:  Stat Med       Date:  2010-03-30       Impact factor: 2.373

6.  On the C-statistics for evaluating overall adequacy of risk prediction procedures with censored survival data.

Authors:  Hajime Uno; Tianxi Cai; Michael J Pencina; Ralph B D'Agostino; L J Wei
Journal:  Stat Med       Date:  2011-01-13       Impact factor: 2.373

7.  Use of the proposals of the international association for the study of lung cancer in the forthcoming edition of lung cancer staging system to predict long-term prognosis of operated patients.

Authors:  Ottavio Rena; Fabio Massera; Mario Robustellini; Esther Papalia; Rocco Delfanti; Elena Lisi; Emanuele Pirondini; Davide Turello; Caterina Casadio
Journal:  Cancer J       Date:  2010 Mar-Apr       Impact factor: 3.360

8.  Visceral pleural invasion classification in non-small-cell lung cancer in the 7th edition of the tumor, node, metastasis classification for lung cancer: validation analysis based on a large-scale nationwide database.

Authors:  Akikazu Kawase; Junji Yoshida; Etsuo Miyaoka; Hisao Asamura; Yoshitaka Fujii; Yoichi Nakanishi; Kenji Eguchi; Masaki Mori; Noriyoshi Sawabata; Meinoshin Okumura; Kohei Yokoi
Journal:  J Thorac Oncol       Date:  2013-05       Impact factor: 15.609

9.  Re-evaluation of the prognostic value of visceral pleura invasion in Stage IB non-small cell lung cancer using the prospective multicenter ACOSOG Z0030 trial data set.

Authors:  Juan J Fibla; Stephen D Cassivi; Alessandro Brunelli; Paul A Decker; Mark S Allen; Gail E Darling; Rodney J Landreneau; Joe B Putnam
Journal:  Lung Cancer       Date:  2012-10-03       Impact factor: 5.705

10.  A flexible alternative to the Cox proportional hazards model for assessing the prognostic accuracy of hospice patient survival.

Authors:  Branko Miladinovic; Ambuj Kumar; Rahul Mhaskar; Sehwan Kim; Ronald Schonwetter; Benjamin Djulbegovic
Journal:  PLoS One       Date:  2012-10-17       Impact factor: 3.240

View more
  11 in total

1.  Development and validation of a preoperative noninvasive predictive model based on circular tumor DNA for lymph node metastasis in resectable non-small cell lung cancer.

Authors:  Rusi Zhang; Xuewen Zhang; Zirui Huang; Fang Wang; Yongbin Lin; Yingsheng Wen; Li Liu; Jinbo Li; Xinyi Liu; Wenzhuan Xie; Mengli Huang; Gongming Wang; Longjun Yang; Dechang Zhao; Xiangyang Yu; Kexing Xi; Weidong Wang; Ling Cai; Lanjun Zhang
Journal:  Transl Lung Cancer Res       Date:  2020-06

2.  Novel Circulating Tumour Cell-Related Risk Model Indicates Prognosis and Immune Infiltration in Lung Adenocarcinoma.

Authors:  Lu Liang; Yueying Liu; Shiyao Jiang; Jingjing Huang; Hua He; Li Shen; Li Cong; Yiqun Jiang
Journal:  J Immunol Res       Date:  2022-05-29       Impact factor: 4.493

3.  New TNM staging in lung cancer (8th edition) and future perspectives.

Authors:  José-María Matilla; M Zabaleta; E Martínez-Téllez; J Abal; A Rodríguez-Fuster; J Hernández-Hernández
Journal:  J Clin Transl Res       Date:  2020-09-02

4.  A predictive model for identifying candidates for adjuvant chemotherapy based on recurrence risk profile of resected, node-negative (N0) non-small cell lung cancer.

Authors:  Timur A Krivitsky; Gavin M Wright; Muteb Al Zaidi
Journal:  J Thorac Dis       Date:  2021-01       Impact factor: 2.895

Review 5.  Validation of the 8th lung cancer TNM classification and clinical staging system in a German cohort of surgically resected patients.

Authors:  Samantha Taber; Joachim Pfannschmidt
Journal:  Innov Surg Sci       Date:  2020-08-12

6.  Relationship Between Pathologic T1 Categories and Pathologic Factors Affecting Prognosis in Pulmonary Adenocarcinoma.

Authors:  Hironori Ninomiya; Kentaro Inamura; Mingyon Mun; Makoto Nishio; Yuichi Ishikawa
Journal:  JTO Clin Res Rep       Date:  2022-02-10

7.  Midterm survival of imaging-assisted robotic lung segmentectomy for non-small-cell lung cancer.

Authors:  Zied Chaari; François Montagne; Matthieu Sarsam; Benjamin Bottet; Philippe Rinieri; Andre Gillibert; Jean Marc Baste
Journal:  Interact Cardiovasc Thorac Surg       Date:  2022-06-01

8.  Nationwide Validation of the 8th American Joint Committee on Cancer TNM Staging System and Five Proposed Modifications for Resected Pancreatic Cancer.

Authors:  Thijs J Schouten; Lois A Daamen; Galina Dorland; Stijn R van Roessel; Vincent P Groot; Marc G Besselink; Bert A Bonsing; Koop Bosscha; Lodewijk A A Brosens; Olivier R Busch; Ronald M van Dam; Arantza Fariña Sarasqueta; Sebastiaan Festen; Bas Groot Koerkamp; Erwin van der Harst; Ignace H J T de Hingh; Martijn Intven; Geert Kazemier; Vincent E de Meijer; Vincent B Nieuwenhuijs; G Mihaela Raicu; Daphne Roos; Jennifer M J Schreinemakers; Martijn W J Stommel; M F van Velthuysen; Robert C Verdonk; Joanne Verheij; Helena M Verkooijen; Hjalmar C van Santvoort; I Quintus Molenaar
Journal:  Ann Surg Oncol       Date:  2022-04-25       Impact factor: 4.339

9.  Decision-making factors for best supportive care alone and prognostic factors after best supportive care in non-small cell lung cancer patients.

Authors:  Haruna Kitazawa; Yuichiro Takeda; Go Naka; Haruhito Sugiyama
Journal:  Sci Rep       Date:  2019-12-27       Impact factor: 4.379

10.  Prognostic Factor and Clinical Outcome in Stage III Non-Small Cell Lung Cancer: A Study Based on Real-World Clinical Data in the Korean Population.

Authors:  Ho Cheol Kim; Wonjun Ji; Jae Cheol Lee; Hyeong Ryul Kim; Si Yeol Song; Chang-Min Choi
Journal:  Cancer Res Treat       Date:  2021-02-16       Impact factor: 4.679

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.